Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab ... Tanezumab and Regeneron/Teva’s fasinumab are the last survivors in a class ...

The global orally disintegrating tablet market size was valued at USD 14.76 billion in 2024 and is projected to grow from USD 16.33 billion in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7 ...

Mark J. Alberts, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Eli Lilly is to buy the private biotech Disarm Therapeutics ... NICE has already recommended Teva’s rival Ajovy (fremanezumab) this year, although it has rejected Novartis’ Aimovig (erenumab ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.